ANNX Annexon, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1528115 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.9%
TTM EPS YoY28.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-130.8%
ROA-83.0%
ROIC (approx.)-293.6%
Asset turnover—
Leverage & solvency
Liabilities / assets43.0%
Debt / equity0.35x
Current ratio5.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $41.37M | $46.59M | $35.79M | $42.66M | $49.70M | $44.16M | $48.18M | $43.35M |
| SG&A expense | $10.87M | $10.64M | $10.27M | $7.60M | $7.32M | $7.57M | $9.23M | $9.12M |
| Operating income | -$52.24M | -$57.23M | -$46.05M | -$50.26M | -$57.02M | -$51.73M | -$57.41M | -$52.48M |
| Interest expense | $833,000 | — | — | — | $0 | — | — | — |
| Net income | -$51.22M | -$55.35M | -$44.14M | -$48.26M | -$54.92M | -$49.16M | -$54.36M | -$48.59M |
| EBITDA | -$51.71M | -$56.69M | -$45.51M | -$49.72M | -$56.47M | -$51.19M | -$56.87M | -$51.94M |
| EPS (basic) | -0.25 | -0.28 | -0.23 | — | -0.37 | -0.34 | -0.37 | — |
| EPS (diluted) | -0.25 | -0.28 | -0.23 | — | -0.37 | -0.34 | -0.37 | — |
| Weighted avg. shares (diluted) | 204.65M | 201.00M | 194.20M | — | 149.12M | 148.32M | 148.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $102.39M | $199.27M | $175.21M | $162.05M | $140.45M | $133.32M | $98.15M | $50.53M |
| Short-term investments | $110.98M | $9.97M | $49.82M | $76.29M | $49.30M | $94.73M | $166.57M | $262.52M |
| Current assets | $217.90M | $212.76M | $228.27M | $242.19M | $192.82M | $230.62M | $268.16M | $316.46M |
| PP&E, net | $9.16M | $9.68M | $10.11M | $10.62M | $11.15M | $11.65M | $12.19M | $12.64M |
| Total assets | $250.41M | $246.07M | $262.89M | $277.57M | $229.14M | $264.57M | $303.03M | $350.07M |
| Current liabilities | $37.66M | $38.48M | $35.94M | $42.63M | $43.58M | $40.64M | $33.55M | $30.51M |
| Long-term debt | $49.34M | — | — | $0 | — | — | — | — |
| Total debt | $49.34M | — | — | $0 | — | — | — | — |
| Total liabilities | $107.61M | $60.01M | $58.35M | $65.92M | $67.70M | $65.56M | $59.24M | $56.97M |
| Shareholders' equity | $142.79M | $186.06M | $204.53M | $211.65M | $161.44M | $199.02M | $243.79M | $293.11M |
| Net debt | -$53.05M | — | — | -$162.05M | — | — | — | — |
| Shares outstanding | — | — | — | 149.36M | — | — | — | 109.38M |
| Cash flow statement | ||||||||
| Operating cash flow | -$48.68M | -$48.01M | -$46.80M | -$45.93M | -$52.30M | -$38.07M | -$50.05M | -$36.02M |
| Capital expenditure | $0 | $137,000 | $0 | $0 | $48,000 | $15,000 | $74,000 | $6,000 |
| Free cash flow | -$48.68M | -$48.14M | -$46.80M | -$45.93M | -$52.35M | -$38.09M | -$50.13M | -$36.02M |
| Investing cash flow | -$100.50M | $39.97M | $27.06M | -$26.52M | $45.87M | $73.08M | $97.62M | $1.01M |
| Financing cash flow | $52.30M | $32.10M | $32.90M | $95.08M | $13.56M | $153,000 | $59,000 | $4.97M |
| Depreciation & amortization | $525,000 | $540,000 | $539,000 | $543,000 | $546,000 | $540,000 | $537,000 | $537,000 |
| Stock-based compensation | $5.11M | $4.81M | $4.16M | $3.31M | $3.83M | $4.21M | $5.08M | $5.22M |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.